Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is projected to report a significant increase in earnings for the third quarter of 2026, driven by higher revenues. The market’s consensus anticipates this growth, but the crucial factor will be how the actual results align with these expectations. A performance exceeding these estimates could positively influence the stock price, while a failure to meet them might have the opposite effect.
The upcoming earnings report will be pivotal, as management’s insights during the earnings call will largely determine the sustainability of any immediate price changes and future earnings forecasts. Understanding the potential for a positive earnings per share (EPS) surprise is valuable for investors looking to gauge the company’s near-term performance.
Zacks Consensus Estimate
Protagonist Therapeutics is expected to announce quarterly earnings of $2.58 per share, which marks an impressive year-over-year increase of 516.1%. Revenue projections stand at $267.01 million, a substantial rise of 5569% compared to the same quarter last year1. Such dramatic growth figures are indicative of the company’s expanding market presence and operational efficiency.
Estimate Revisions Trend
Over the past month, the consensus EPS estimate for the quarter has been revised upward by 42.22%. This reflects a reassessment by analysts, who have collectively adjusted their initial estimates upwards2. However, it’s important to note that an aggregate change may not always indicate the direction of individual analysts’ revisions. These revisions are often based on new information, including market trends and internal company developments, that analysts consider in their evaluations.
Earnings Whisper
Estimate revisions ahead of an earnings release can provide insights into the business conditions for the period in question. The Zacks Earnings ESP (Expected Surprise Prediction) model compares the Most Accurate Estimate to the Zacks Consensus Estimate. A positive Earnings ESP reading suggests a likelihood of an earnings beat, especially when combined with a favorable Zacks Rank of #1 (Strong Buy), #2 (Buy), or #3 (Hold). Research indicates that stocks with this combination tend to exceed expectations about 70% of the time.
For Protagonist Therapeutics, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -14.34%. Despite the stock’s current Zacks Rank of #2, this combination makes it challenging to predict an earnings beat with confidence3. The negative ESP suggests that analysts have become somewhat bearish on the company’s immediate earnings potential.
Historical Performance
Analysts often consider a company’s past performance against consensus estimates when forecasting future earnings. In the previous quarter, Protagonist Therapeutics exceeded expectations by posting earnings of $2.29 per share against an anticipated $2.11, resulting in a positive surprise of 8.53%. Over the last four quarters, the company has surpassed consensus EPS estimates twice4. This track record of beating estimates in half of the recent quarters suggests a certain level of unpredictability in earnings outcomes.
While an earnings beat or miss can influence stock movement, other factors may also impact investor sentiment. Stocks can decline despite an earnings beat due to other disappointing elements, while unforeseen catalysts can help stocks rise despite an earnings miss. Therefore, it’s crucial to consider a company’s Earnings ESP and Zacks Rank before its quarterly release.
Industry Comparison: Qiagen
In the broader Medical – Biomedical and Genetics industry, Qiagen N.V. (NYSE:QGEN) is also set to release its earnings for the quarter ended September 2026. The company is expected to report earnings of $0.63 per share, reflecting a slight year-over-year decline of 1.6%. However, its revenue is projected to increase by 1.3% to $539.44 million. Qiagen’s consensus EPS estimate has remained stable over the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of +4.00%. With a Zacks Rank of #2, this suggests a strong likelihood of Qiagen beating its consensus EPS estimate5.
Investors can stay informed about upcoming earnings announcements using resources like the Zacks Earnings Calendar. This tool provides a comprehensive schedule of earnings releases, helping investors plan their strategies around potential market-moving events.
Footnotes:
- Protagonist Therapeutics is expected to report significant earnings and revenue growth. Source.
- The consensus EPS estimate for Protagonist Therapeutics has been revised upward by 42.22%. Source.
- Protagonist Therapeutics has an Earnings ESP of -14.34%. Source.
- Protagonist Therapeutics exceeded earnings expectations in the previous quarter. Source.
- Qiagen is expected to report earnings with a positive Earnings ESP. Source.
Featured Image: DepositPhotos @ JanPietruszka
